Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of lafutidine and composition, applied in the field of oral solid pharmaceutical compositions, can solve problems such as poor stability, patient compliance and the like
Inactive Publication Date: 2009-06-24
BEIJING D VENTUREPHARM TECH DEV
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] Chinese patent 021359601 discloses a lafutidine injection and its preparation method. Because the injection has poor stability and patient compliance problems during use, the present invention is dedicated to developing a stable lafutidine injection with high dissolution rate. oral solid dosage form
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0019]
[0020] Preparation Process:
[0021] Weigh the prescribed amount of lafutidine, lactose, and microcrystalline cellulose, mix them evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add magnesium stearate , mixed and pressed into tablets.
Embodiment 2
[0023]
[0024] Preparation Process:
[0025] Weigh the prescribed amount of lafutidine, lactose, and microcrystalline cellulose, mix them evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add butylated hydroxyanisole , magnesium stearate, mixed evenly and compressed into tablets.
Embodiment 3
[0027]
[0028] Preparation Process:
[0029] Lafutidine and Polyethylene Glycol 6000 of prescription quantity are dissolved in 70% ethanol solution, after stirring and dissolving, spin evaporated to dryness to obtain solid mixture, powdered into fine powder, then mixed with lactose, microcrystalline cellulose Mix evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add BHA and magnesium stearate, mix evenly, and press into tablets.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to an oral solid medicine composition containing lafutidine, which comprises an active ingredient, namely lafutidine and salt thereof, a solid dispersant, an antioxidant and other pharmaceutical excipients, and can be used for treating peptic ulcer.
Description
Technical field: [0001] The invention relates to an oral pharmaceutical composition, in particular to an oral solid pharmaceutical composition containing lafutidine. Background technique: [0002] Gastrointestinal diseases are common and frequently-occurring diseases. In recent years, with the increase in the incidence of digestive system diseases, the proportion of drugs used for gastrointestinal diseases in the entire clinical medicine is increasing. Commonly used drugs for the treatment of peptic ulcer are ranitidine and famotidine. This year, a new H 2 Receptor antagonist - lafutidine. [0003] The chemical name of lafutidine: (±)-2-(2-furanmethylsulfinyl)-N-[4-[4-(1-piperidylmethyl)-2-pyridyloxy]-cis -2-butenyl]acetamide. This product can reduce the basal secretion of gastric acid and inhibit the secretion of gastric acid stimulated by histamine, gastrin and urethane. Compared with ranitidine and famotidine, this product has a higher effect on H 2 The blocking effec...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more